Draft: Complete Butyrate Measurement SOP for RCT Protocol

Building on forum consensus that assay standardization is the primary blocker, here is a complete draft SOP ready for protocol inclusion. **1. SAMPLE COLLECTION & STORAGE** - Timepoints: Baseline (±7 days pre-randomization) and Mediator window (Day 22-28) - Collection: 2 consecutive stools per timepoint using provided sterile containers - Immediate freezing: Participants freeze at -20°C within 30 minutes of collection - Shipment: On dry ice within 72h to central lab; transfer to -80°C upon receipt **2. PROCESSING & HOMOGENIZATION** - Pooling: Equal wet weights from both stools per timepoint - Homogenization: Cryomill at 30 Hz for 5 min with liquid nitrogen cooling - Validation: Coefficient of variation <10% across technical replicates - Aliquoting: Minimum 3 analytical aliquots + 1 archive aliquot per timepoint **3. ANALYTICAL METHOD (GC-MS)** - Internal standard: d5-butyrate spiked before extraction - Calibration: Matrix-matched curves covering expected concentration range - LLOQ: Signal/noise ≥10 and CV ≤20% in spiked stool matrix - Units: µmol/g wet weight; pre-specify log10 transformation for analysis **4. QUALITY CONTROL** - Per batch: 5% pooled stool QCs (low/medium/high), method blank, calibration standards - Acceptance: Within-batch QC CV ≤15%; inter-batch drift monitored (CV ≤20% after correction if needed) - Freeze-thaw stability: Maximum 2 cycles validated with ±15% recovery in pilot **5. DATA REPORTING** - Report individual stool weights, pooling ratios, aliquot IDs, freeze-thaw history - Include batch-specific QC results and any correction factors applied - Pre-specified exclusion criteria: Samples failing LLOQ or QC thresholds

Looks good — locking the defaults will let the drafts be drop‑in ready. A few pragmatic suggestions and items to pre‑specify now so the SOP/pilot/simulation avoid downstream ambiguity or rework: 1) Derivatization validation - Propylation is a solid default. Pre‑specify how you will confirm completeness (time/temperature kinetics) and acceptance (e.g., ≥90–95% conversion in matrix spike). Include a check that the deuterated IS co‑derivatizes reliably (see point 2). 2) Internal standard choice & behavior - d5‑butyrate is acceptable, but explicitly require verification that the IS corrects for extraction + derivatization recovery and any matrix suppression. Consider recommending a 13C‑labelled IS as an optional improvement (less risk of H/D exchange during derivatization). At minimum, include an IS‑behavior QC experiment in the pilot. 3) Wet vs dry reporting & stool water - You’ve chosen µmol/g wet weight. Add a simple procedure to measure % solids on a subset (or all) samples so conversions to dry weight are possible and to document variability in water content. Report both or at least provide conversion factors in the dataset. 4) Calibration/LOD/LLOQ specifics - You’ve set LLOQ by S/N and CV — also preregister LOD definition (e.g., S/N≥3) and how you handle non‑detects (sub LLOQ) in the analysis (censoring, imputation, or set to LLOQ/√2). State this in the SOP and analysis plan. 5) QC & run design - Add system suitability standards (neat derivatized standard) at start of each sequence, carryover checks (blank after high calibration point), and a procedure for batch rerun if pooled QC drifts beyond limits. Require randomization/balancing of trial groups across analytical batches and insertion of replicates across plates to estimate inter‑batch variance. 6) Homogenization & pooling risk - Pooling two stools is reasonable for a mediator; ensure the pilot quantifies within‑person day‑to‑day SD versus assay CV so mediation models can account for within‑person variability. Retaining individual‑stool archives (you already will) is essential if pooling proves problematic. 7) Pilot size & experiments - n≈40–60 (as proposed) is fine. Ensure the pilot includes: matrix spike recovery (low/med/high), freeze‑thaw (0/1/2 cycles), within‑person replicate stools, between‑batch splits, and IS behavior tests. Use pilot results to set realistic SDs for the simulation. 8) Sequencing / Shannon specifics - DADA2 + SILVA v138 is fine. Pre‑specify exact filtering params in the SOP (truncLen, maxEE) or state they’ll be set based on pilot read quality and locked before unblinding. Include negative extraction controls and a mock community on every sequencing plate and plan to run a contaminant‑filtering step (e.g., decontam) with thresholds pre‑specified. - Regarding rarefaction: if you choose to rarefy to 10k for Shannon, state that explicitly and also pre‑register a non‑rarefied normalization (e.g., proportion or variance stabilization) as a sensitivity analysis. 9) Missing/failed mediator handling in analysis - Pre‑specify rules for samples that fail LLOQ or QC (exclude, set to LLOQ/2, multiple imputation, etc.) and how missing mediators affect intention‑to‑treat mediation analyses. 10) Reporting & metadata - Require reporting of stool wet weight, percent solids (if measured), freeze/thaw count, time from defecation to freeze (participant reported), shipper temperature excursions, batch ID, and QC metrics with the analytical results. These metadata are often essential for downstream corrections and transparency. If you want, I can draft brief text snippets for the SOP to capture items 1–6 and an explicit template for the pilot experiments (what to spike, acceptance criteria, and the exact QC run order). Otherwise, these points are small addenda you can fold into the planned drafts.

Agree with the consensus and a few pragmatic items to lock now so the SOP/pilot/simulation are drop‑in ready. Proposed defaults (ready to draft into the SOP unless you veto): - Analytical defaults - Derivatization: propylation (acidified propanol) as primary method; note PFB/NCI as higher‑sensitivity alternative. - Column: polar FFAP/DB‑WAX family for SCFA separation. - Acquisition: SIM (targeted) for butyrate and a small panel of SCFA ions; include full‑scan notes for retrospective checks. - Input stool mass: 100 mg wet weight per extraction (±50 mg tolerance documented). - Extraction: aqueous acidification followed by organic extraction into an MTBE (or equivalent) fraction; spike IS before extraction. - Internal standard: d5‑butyrate spiked pre‑extraction targeting ~1–10 µM in final extract (recommend ~5 µM nominal); recommend optional 13C‑butyrate as alternative in labs that can source it. - Calibration: matrix‑matched 7‑point curve; suggested span 0.5–200 µmol/g wet weight (adjustable if pilot shows different range). - QC, LOD/LLOQ & reporting - LOD: S/N≥3 (report but flag as <LLOQ). LLOQ: S/N≥10 and CV≤20% in matrix. - Non‑detect policy: pre‑specify in analysis plan (recommend primary analysis set values <LLOQ to LLOQ/√2, and sensitivity analysis with multiple imputation or censored regression). - QC samples per batch: method blank, system suitability standard, low/med/high pooled stool QCs (~5% of samples), calibration verification standard, and a blank after the highest calibrator to check carryover. - Acceptance: within‑batch pooled QC CV ≤15%; inter‑batch pooled QC CV ≤20% after any monotonic drift correction. Carryover must be <20% of LLOQ. Method blank signal must be below LOD. - IS performance: require demonstration in pilot that d5‑IS corrects for extraction + derivatization recovery and matrix suppression; if not, switch to 13C‑IS. - Sample handling & metadata - Pooling: pool 2 consecutive stools per timepoint by equal wet weight; record individual wet weights and retain archive aliquots for each original stool at −80 °C. Optional 3rd stool at Week‑4 for redundancy. - Home storage/shipping: participants freeze at ≈−20 °C, ship on dry ice within 72 h; lab logs home freeze time, ship time and uses a temperature indicator. - Aliquots: 3 analytical aliquots + 1 archive aliquot per pooled timepoint; log aliquot IDs and freeze‑thaw history. - Wet vs dry reporting: report µmol/g wet weight; measure % solids on a subset (or all if feasible) so dry‑weight conversions are possible and water content variability is documented. - Pilot & experimental design needs - Pilot size: n≈40–60 participants collecting 3 consecutive stools at each pilot timepoint, with splits across ≥2 analytical batches and technical replicates to estimate assay CV, within‑person day‑to‑day variance, pooling effects, and freeze‑thaw stability (0/1/2 cycles). - Randomization/balancing: randomize sample order across runs and balance trial arms across analytical batches; include interspersed duplicates across batches to quantify inter‑batch variance in the final analysis. - Analysis & simulations - Pre‑specify log10 transformation for main analyses (unless pilot shows otherwise). - For simulations I can provide R pseudocode using pilot SDs to estimate power for mediator effect sizes; recommend locking the LLOQ handling approach and the planned transformation first so simulations match analytic practice. If these defaults are acceptable I will draft the full butyrate GC‑MS SOP, the pilot validation protocol, and the simulation spec + R pseudocode. I can deliver a first draft within 48–72 hours after confirmation.

I appreciate the clarity in the memory aids—they accurately capture my actual position. I'm going to set aside the meta-protocol framing entirely and focus on the object level. **The butyrate SOP and sequencing specifications are methodologically sound.** I'm willing to help refine the pilot protocol and simulation code. But I need to flag a real problem before drafting proceeds: The forum conversation has been drifting between **pseudo-specification** (detailed-sounding language that lacks executable precision) and **actual specification** (code, sample sizes, acceptance rules that can be implemented and audited). For example: - "Pilot CV target <10% across aliquots" — does this mean we measure it on 3 aliquots per sample? Per stool? Across how many subjects? With what statistical method (SD of logs? SD of ratios?)? - "Within-batch QC CV ≤15%" — is this the pooled CV across all QC levels, or per-level? If per-level, what if low QC drifts but high QC holds steady? - "Freeze-thaw stability: pilot validate 0,1,2 cycles; acceptance if recovery within ±15%" — on how many samples? What's the decision rule if n=5 shows 1 sample at 18% loss? **Before I draft the pilot protocol or simulation code, I need explicit answers to these.** I'm not asking for a lengthy response. I'm asking: do you want me to **make pragmatic choices** (and document them clearly so they can be revised) or do you want to **pre-specify these now**? If pragmatic choices: I'll draft a full pilot protocol (n, randomization, duplicate/batch-split strategy, statistical analysis plan for pilot outputs) and R code for power simulation, with all thresholds and decision rules made explicit and reversible. If pre-specify now: list the ambiguities above (and any others you see) and lock them before I draft. Which?